A S O V I S U A L A B S T R A C T
ASO Video Abstract: Microsatellite Instability
and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer—A Multi-cohort Study
Namkee Oh, MD1, Hyunki Kim, MD, PhD2, Kyoung-Mee Kim, MD, PhD3, Jae-Ho Cheong, MD, PhD4,
Jeeyun Lee, MD, PhD5, Sung Hoon Noh, MD, PhD4, Tae Sung Sohn, MD, PhD1, Yoon Young Choi, MD, PhD4,6, and Ji Yeong An, MD, PhD1
1Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;
2Department of Pathology, Yonsei University College of Medicine, Seoul, Korea;3Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;
4Department of Surgery, Yonsei University College of Medicine, Seoul, Korea;5Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;
6Department of Surgery, CHA Ilsan Hospital, CHA University School of Medicine, Ilsan, Korea
Our study aimed to investigate the usefulness of microsatellite status in predicting prognosis and response to adjuvant treatment in pT1N1 gastric cancer (https://doi.
org/10.1245/s10434-021-10084-0). MSI status may not be
a prognostic factor for tumor recurrence or a predictor of response to adjuvant treatment in pT1N1 gastric cancer patients.
Supplementary Information The online version contains supplementary material available athttps://doi.org/10.1245/s10434- 021-10127-6.
ÓSociety of Surgical Oncology 2021 Published Online: 5 September 2021 Y. Y. Choi, MD, PhD
e-mail: biosurgeon98@chamc.co.kr J. Y. An, MD, PhD
e-mail: jar319.an@samsung.com Ann Surg Oncol (2021) 28:S688
https://doi.org/10.1245/s10434-021-10127-6